Market Cap 12.17M
Revenue (ttm) 1.18M
Net Income (ttm) -1.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -100.00%
Debt to Equity Ratio 0.40
Volume 9,500
Avg Vol 20,456
Day's Range N/A - N/A
Shares Out 4.85M
Stochastic %K 2%
Beta 1.56
Analysts Strong Sell
Price Target $22.00

Company Profile

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multip...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 642 9100
Fax: 972 8 642 9101
Address:
Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel
ValuePrince
ValuePrince Sep. 13 at 12:24 PM
$BLRX 🍓
0 · Reply
MaxProfitTrades
MaxProfitTrades Sep. 8 at 12:34 AM
$BLRX 😎 Interesting
0 · Reply
aojjaijaas9
aojjaijaas9 Sep. 5 at 11:23 PM
0 · Reply
ZacksSCR
ZacksSCR Sep. 1 at 4:06 PM
$BLRX: New GLIX1 Data Touts Synergies https://buff.ly/S5uXzi3
0 · Reply
tankwfwf
tankwfwf Aug. 31 at 6:56 PM
$BLRX In the next day or 2 H.C. Wainwright will value Blrx above 20 dollars. This is the same playbook phil uses when he is slowly putting the knife in investors backs. You can bet the offering is helping one or two of his hedge fund Buddies. Phil talks about a collaboration with another firm. Every collaboration he has made has helped him and the board, not investors. Remember Phil is a liar and a thief.
0 · Reply
focafoca99
focafoca99 Aug. 31 at 2:56 PM
$BLRX targeted a $3.75 million registered direct offering of 480,696 ADSs and related warrants, closing expected end of August.
0 · Reply
StockMarketToday247
StockMarketToday247 Aug. 31 at 2:32 PM
$GOVX $WKSP $AMIX $BLRX — the tickers are examples; the financing pattern is the point. Recent micro-cap deals are turning old warrant overhang into cash now while issuing a fresh layer of future dilution optionality. Replacement coverage in verified inducements has ranged roughly 100%–200%. So “raised $4M” is not enough. I want the repricing, replacement coverage, term, agent economics and registration/covenant package. Sometimes this is rational versus a discounted stock sale. The terms are a bargaining-power signal, not an automatic sell signal. The interesting screen: large OTM warrant cohorts + shrinking runway + shelf capacity + concentrated holders. That’s where I’ve got my eyes today. https://stockmarkettoday.beehiiv.com/p/micro-caps-are-raising-cash-by-rolling-dilution-forward
1 · Reply
EarningsInsider
EarningsInsider Aug. 31 at 2:30 PM
https://www.marketbeat.com/earnings/reports/2026-8-31-biolinerx-ltd-stock/ $BLRX BioLineRx Earnings Transcript
0 · Reply
DonCorleone77
DonCorleone77 Aug. 31 at 1:08 PM
$SAIC $BLRX $GME $SLB $HAL PRE-MARKET MOVERS: Currently Higher After Earnings: - SAIC (SAIC) up 12.1% - BioLineRx (BLRX) up 5.0% - GameStop (GME) up 3.8% Currently Also Higher: - SLB (SLB) up 1.9% after signing an agreement to acquire Kelvion for $3.4B in cash Currently Higher Following Renewed Strikes in the Middle East: - Halliburton (HAL) up 2.7% - Chevron (CVX) up 2.3% - Valero (VLO) up 2.1% - Occidental (OXY) up 2.4% - Exxon Mobil (XOM) up 2.2% Currently Lower: - PG&E (PCG), Edison International (EIX) and Sempra Energy (SRE) down 18.9%, 19.9% and 3.6%, respectively, after KCRA reported California lawmakers are barring Governor Gavin Newsom from moving forward with his plan to prevent insurers in the state from recouping their losses from investor-owned utilities that cause a catastrophic wildfire - Tela Bio (TELA) down 4.0% after announcing that Roberto Cuca, COO and CFO, will step down from the role effective immediately - Pinterest (PINS) down 3.6% after disclosing that Julia Brau Donnelly, CFO, submitted her resignation to Pinterest to pursue another opportunity - Aon plc (AON) down 1.8% after entering a definitive agreement to acquire USI from KKR (KKR) and other shareholders for a total purchase price of $17B
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 31 at 11:24 AM
$BLRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.00 • Reported revenue of $0.29M down -3.33% YoY • BioLineRx is maintaining its cash runway guidance into the first half of 2027, supported by $13.1M in cash, cash equivalents, and short-term bank deposits as of June 30, 2026.
0 · Reply
Latest News on BLRX
BioLineRx Releases Q2 2026 Financial Results

2026-08-31T12:48:21.000Z - 13 days ago

BioLineRx Releases Q2 2026 Financial Results


BioLineRx Earnings Call Transcript: Q2 2026

Aug 31, 2026, 8:30 AM EDT - 13 days ago

BioLineRx Earnings Call Transcript: Q2 2026


BioLineRx Earnings release: Q2 2026

Aug 31, 2026, 8:30 AM EDT - 13 days ago

BioLineRx Earnings release: Q2 2026


BioLineRx reports Q2 EPS 0c vs 0c last year

2026-08-31T11:10:23.000Z - 13 days ago

BioLineRx reports Q2 EPS 0c vs 0c last year


BioLineRx to Report Second Quarter 2026 Results on August 31, 2026

Tue, 25 Aug 2026 07:00:00 -0400 - 19 days ago

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026


BioLineRx (BLRX) Q1 2026 Earnings Transcript

2026-05-29T18:16:10.000Z - 3 months ago

BioLineRx (BLRX) Q1 2026 Earnings Transcript


BioLineRx Earnings Call Transcript: Q1 2026

May 27, 2026, 8:30 AM EDT - 3 months ago

BioLineRx Earnings Call Transcript: Q1 2026


BioLineRx Earnings release: Q1 2026

May 27, 2026, 8:30 AM EDT - 3 months ago

BioLineRx Earnings release: Q1 2026


BioLineRx reports Q1 EPS 0c vs. (0c) last year

2026-05-27T11:28:44.000Z - 3 months ago

BioLineRx reports Q1 EPS 0c vs. (0c) last year


BioLineRx to Present GLIX1 Preclinical Data at ASCO 2026

2026-05-22T17:10:56.000Z - 3 months ago

BioLineRx to Present GLIX1 Preclinical Data at ASCO 2026


BioLineRx to Report First Quarter 2026 Results on May 27, 2026

Wed, 20 May 2026 07:00:00 -0400 - 3 months ago

BioLineRx to Report First Quarter 2026 Results on May 27, 2026


BioLineRx (BLRX) Partners in Groundbreaking Glioblastoma Trial

2026-04-08T10:50:48.000Z - 5 months ago

BioLineRx (BLRX) Partners in Groundbreaking Glioblastoma Trial


BioLineRx, Hemispherian initiate clinical trial of GLIX1

2026-04-08T09:26:21.000Z - 5 months ago

BioLineRx, Hemispherian initiate clinical trial of GLIX1


Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma

Wed, 08 Apr 2026 02:30:00 -0400 - 5 months ago

Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma


BioLineRx initiates Phase 1/2a study of GLIX1

2026-03-26T11:08:04.000Z - 5 months ago

BioLineRx initiates Phase 1/2a study of GLIX1


BioLineRx Earnings Call Transcript: Q4 2025

Mar 23, 2026, 8:30 AM EDT - 5 months ago

BioLineRx Earnings Call Transcript: Q4 2025


BioLineRx Annual report: Q4 2025

Mar 23, 2026, 8:30 AM EDT - 5 months ago

BioLineRx Annual report: Q4 2025


BioLineRx Earnings release: Q4 2025

Mar 23, 2026, 8:30 AM EDT - 5 months ago

BioLineRx Earnings release: Q4 2025


Earnings Scheduled For March 23, 2026

2026-03-23T11:11:27.000Z - 5 months ago

Earnings Scheduled For March 23, 2026


BioLineRx provides corporate update

2026-03-23T11:10:51.000Z - 5 months ago

BioLineRx provides corporate update


BioLineRx Reports 2025 Financial Results and Provides Corporate Update

Mon, 23 Mar 2026 07:00:00 -0400 - 5 months ago

BioLineRx Reports 2025 Financial Results and Provides Corporate Update


BioLineRx (BLRX) and Others Set to Announce Earnings

2026-03-23T00:55:17.000Z - 5 months ago

BioLineRx (BLRX) and Others Set to Announce Earnings


BioLineRx to Report 2025 Annual Results on March 23, 2026

Mon, 16 Mar 2026 07:00:00 -0400 - 6 months ago

BioLineRx to Report 2025 Annual Results on March 23, 2026


BioLineRx Earnings Call Transcript: Q3 2025

Nov 24, 2025, 8:30 AM EST - 9 months ago

BioLineRx Earnings Call Transcript: Q3 2025


BioLineRx Earnings release: Q3 2025

Nov 24, 2025, 8:30 AM EST - 9 months ago

BioLineRx Earnings release: Q3 2025


BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture

2025-11-24T12:34:08.000Z - 9 months ago

BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture


BioLineRx reports Q3 EPS 0c vs 0c last year

2025-11-24T12:05:10.000Z - 9 months ago

BioLineRx reports Q3 EPS 0c vs 0c last year


Earnings Scheduled For November 24, 2025

2025-11-24T11:11:10.000Z - 9 months ago

Earnings Scheduled For November 24, 2025


BioLine Rx's Earnings: A Preview

2025-11-21T15:01:37.000Z - 9 months ago

BioLine Rx's Earnings: A Preview


BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Tue, 18 Nov 2025 07:00:00 -0500 - 9 months ago

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025


BioLineRx Slides: Corporate Presentation

Nov 18, 2025, 7:00 AM EST - 9 months ago

BioLineRx Slides: Corporate Presentation


BioLineRx Transcript: Study Update

Sep 29, 2025, 8:30 AM EDT - 11 months ago

BioLineRx Transcript: Study Update


BioLineRx Press release: Study Update

Sep 29, 2025, 8:30 AM EDT - 11 months ago

BioLineRx Press release: Study Update


BioLineRx Slides: Study Update

Sep 29, 2025, 8:30 AM EDT - 11 months ago

BioLineRx Slides: Study Update


BioLineRx Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Earnings Call Transcript: Q2 2025


BioLineRx Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Earnings release: Q2 2025


BioLineRx reports Q2 EPS 0c vs. 0c last year

2025-08-14T11:05:57.000Z - 1 year ago

BioLineRx reports Q2 EPS 0c vs. 0c last year


BioLineRx Earnings Call Transcript: Q1 2025

May 27, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Earnings Call Transcript: Q1 2025


BioLineRx Earnings release: Q1 2025

May 27, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Earnings release: Q1 2025


BioLineRx Earnings Call Transcript: Q4 2024

Mar 31, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Earnings Call Transcript: Q4 2024


BioLineRx Annual report: Q4 2024

Mar 31, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Annual report: Q4 2024


BioLineRx Earnings release: Q4 2024

Mar 31, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Earnings release: Q4 2024


BioLineRx to Report 2024 Annual Results on March 31, 2025

Mar 24, 2025, 7:00 AM EDT - 1 year ago

BioLineRx to Report 2024 Annual Results on March 31, 2025


BioLineRx Issues Letter to Shareholders

Jan 21, 2025, 7:00 AM EST - 1 year ago

BioLineRx Issues Letter to Shareholders


BioLineRx Announces $10 Million Registered Direct Offering

Jan 6, 2025, 8:57 AM EST - 1 year ago

BioLineRx Announces $10 Million Registered Direct Offering


BioLineRx Earnings Call Transcript: Q3 2024

Nov 25, 2024, 8:30 AM EST - 1 year ago

BioLineRx Earnings Call Transcript: Q3 2024


BioLineRx Earnings release: Q3 2024

Nov 25, 2024, 8:30 AM EST - 1 year ago

BioLineRx Earnings release: Q3 2024


BioLineRx Earnings Call Transcript: Q2 2024

Aug 15, 2024, 8:30 AM EDT - 2 years ago

BioLineRx Earnings Call Transcript: Q2 2024


BioLineRx Earnings release: Q2 2024

Aug 15, 2024, 8:30 AM EDT - 2 years ago

BioLineRx Earnings release: Q2 2024


BioLineRx Earnings Call Transcript: Q1 2024

May 28, 2024, 8:30 AM EDT - 2 years ago

BioLineRx Earnings Call Transcript: Q1 2024


BioLineRx Earnings release: Q1 2024

May 28, 2024, 8:30 AM EDT - 2 years ago

BioLineRx Earnings release: Q1 2024


BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 22, 2024, 7:00 AM EDT - 2 years ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024


BioLineRx Announces $6 Million Registered Direct Offering

Apr 1, 2024, 9:00 AM EDT - 2 years ago

BioLineRx Announces $6 Million Registered Direct Offering


BioLineRx Earnings Call Transcript: Q4 2023

Mar 26, 2024, 8:30 AM EDT - 2 years ago

BioLineRx Earnings Call Transcript: Q4 2023


BioLineRx Annual report: Q4 2023

Mar 26, 2024, 8:30 AM EDT - 2 years ago

BioLineRx Annual report: Q4 2023


BioLineRx Earnings release: Q4 2023

Mar 26, 2024, 8:30 AM EDT - 2 years ago

BioLineRx Earnings release: Q4 2023


ValuePrince
ValuePrince Sep. 13 at 12:24 PM
$BLRX 🍓
0 · Reply
MaxProfitTrades
MaxProfitTrades Sep. 8 at 12:34 AM
$BLRX 😎 Interesting
0 · Reply
aojjaijaas9
aojjaijaas9 Sep. 5 at 11:23 PM
0 · Reply
ZacksSCR
ZacksSCR Sep. 1 at 4:06 PM
$BLRX: New GLIX1 Data Touts Synergies https://buff.ly/S5uXzi3
0 · Reply
tankwfwf
tankwfwf Aug. 31 at 6:56 PM
$BLRX In the next day or 2 H.C. Wainwright will value Blrx above 20 dollars. This is the same playbook phil uses when he is slowly putting the knife in investors backs. You can bet the offering is helping one or two of his hedge fund Buddies. Phil talks about a collaboration with another firm. Every collaboration he has made has helped him and the board, not investors. Remember Phil is a liar and a thief.
0 · Reply
focafoca99
focafoca99 Aug. 31 at 2:56 PM
$BLRX targeted a $3.75 million registered direct offering of 480,696 ADSs and related warrants, closing expected end of August.
0 · Reply
StockMarketToday247
StockMarketToday247 Aug. 31 at 2:32 PM
$GOVX $WKSP $AMIX $BLRX — the tickers are examples; the financing pattern is the point. Recent micro-cap deals are turning old warrant overhang into cash now while issuing a fresh layer of future dilution optionality. Replacement coverage in verified inducements has ranged roughly 100%–200%. So “raised $4M” is not enough. I want the repricing, replacement coverage, term, agent economics and registration/covenant package. Sometimes this is rational versus a discounted stock sale. The terms are a bargaining-power signal, not an automatic sell signal. The interesting screen: large OTM warrant cohorts + shrinking runway + shelf capacity + concentrated holders. That’s where I’ve got my eyes today. https://stockmarkettoday.beehiiv.com/p/micro-caps-are-raising-cash-by-rolling-dilution-forward
1 · Reply
EarningsInsider
EarningsInsider Aug. 31 at 2:30 PM
https://www.marketbeat.com/earnings/reports/2026-8-31-biolinerx-ltd-stock/ $BLRX BioLineRx Earnings Transcript
0 · Reply
DonCorleone77
DonCorleone77 Aug. 31 at 1:08 PM
$SAIC $BLRX $GME $SLB $HAL PRE-MARKET MOVERS: Currently Higher After Earnings: - SAIC (SAIC) up 12.1% - BioLineRx (BLRX) up 5.0% - GameStop (GME) up 3.8% Currently Also Higher: - SLB (SLB) up 1.9% after signing an agreement to acquire Kelvion for $3.4B in cash Currently Higher Following Renewed Strikes in the Middle East: - Halliburton (HAL) up 2.7% - Chevron (CVX) up 2.3% - Valero (VLO) up 2.1% - Occidental (OXY) up 2.4% - Exxon Mobil (XOM) up 2.2% Currently Lower: - PG&E (PCG), Edison International (EIX) and Sempra Energy (SRE) down 18.9%, 19.9% and 3.6%, respectively, after KCRA reported California lawmakers are barring Governor Gavin Newsom from moving forward with his plan to prevent insurers in the state from recouping their losses from investor-owned utilities that cause a catastrophic wildfire - Tela Bio (TELA) down 4.0% after announcing that Roberto Cuca, COO and CFO, will step down from the role effective immediately - Pinterest (PINS) down 3.6% after disclosing that Julia Brau Donnelly, CFO, submitted her resignation to Pinterest to pursue another opportunity - Aon plc (AON) down 1.8% after entering a definitive agreement to acquire USI from KKR (KKR) and other shareholders for a total purchase price of $17B
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 31 at 11:24 AM
$BLRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.00 • Reported revenue of $0.29M down -3.33% YoY • BioLineRx is maintaining its cash runway guidance into the first half of 2027, supported by $13.1M in cash, cash equivalents, and short-term bank deposits as of June 30, 2026.
0 · Reply
TwongStocks
TwongStocks Aug. 31 at 11:10 AM
$BLRX BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.prnewswire.com/news-releases/biolinerx-reports-second-quarter-2026-financial-results-and-provides-corporate-update-302864836.html • $13.1M cash as of June 30, runway into 1H 2027. • Aphexda royalty revenue $304K, from sales of $1.6M by Ayrmid last quarter. Lower than Q1 - $477K in royalty revenue from $2.7M in sales. • Net loss last qtr $4.339M. • CheMo4METPANC futility analysis still on track for 2026. • GLIX1 clinical and pre-clinical data have been accepted for publication at the EANO Conference in Sept 2026 and at the SNO Annual Meeting in Nov 2026. • GLIX1 Ph1/2b trial, 2nd of five planned cohorts ongoing in GBM; third patient cohort expected to commence dosing in September.
0 · Reply
Professionall
Professionall Aug. 31 at 9:40 AM
$BLRX Dilutions and the stock goes up? How is that?
0 · Reply
tankwfwf
tankwfwf Aug. 28 at 2:50 PM
$BLRX Phil just covered his pay for the next 3 years....remember Phil is a liar and a thief
0 · Reply
TwongStocks
TwongStocks Aug. 28 at 12:04 PM
$BLRX BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement https://www.prnewswire.com/news-releases/biolinerx-announces-3-75-million-registered-direct-offering-and-concurrent-private-placement-302862746.html • 1,348,921 ADS at a purchase price of $2.78, in a registered direct offering. • Warrants to purchase 2,023,382 ADS with a $2.78 exercise price, in a concurrent private placement. • They also entered into a warrant amendment with the investor in the offering. Warrants to purchase 277,273 ADSs that were previously issued in other offerings were reduced to $2.78 and now expire Aug 2031. • Closing expected Aug 31. Aggregate gross proceeds are expected to be $3.75 million.
0 · Reply
Eran1983
Eran1983 Aug. 27 at 8:03 AM
$BLRX the only thing Phil should explain ..compensation to him? Really?
1 · Reply
focafoca99
focafoca99 Aug. 25 at 11:18 AM
$BLRX set its second-quarter 2026 results release for Aug. 31, with a pre-market conference call at 8:30 a.m. EDT.
0 · Reply
TwongStocks
TwongStocks Aug. 24 at 10:26 AM
$BLRX Earnings call for Q2 2026 scheduled Aug 31 at 8:30am ET https://www.veidan-conferencing.com/bioline-rx-link
0 · Reply
BigWaveOperator
BigWaveOperator Aug. 21 at 10:18 PM
$BLRX been on my ML for years. Total POS
0 · Reply
TwongStocks
TwongStocks Aug. 18 at 8:13 PM
$BLRX Shareholder meeting Sept 23. https://www.sec.gov/Archives/edgar/data/1498403/000117891326004184/exhibit_99-1.htm Proposals 1) Elect Dr. Aharon Schwartz, Dr. Sandra Panem and Dr. Shaoyu Yan as Class III directors 2) Increase authorized shares from 20,000,000,000 ordinary shares (represented by 33,333,333 ADSs on NASDAQ) to 100,000,000,000 ordinary shares (represented by 166,666,667 ADSs). As of August 10, 2026, there were 2,620,977,190 Ordinary Shares (represented by 4,368,295 ADSs) issued and outstanding. 3) Approve equity awards to Phil Serlin. Options to purchase 94,900 ADSs , at an exercise price of $3.33. And PSUs for 73,500 ADSs. 4) Approve equity awards for the Board of Directors. 10,000 ADSs, at an exercise price of $3.33. 5) Approve Kesselman & Kesselman as public accounting firm. Shareholders of record at the close on August 24, 2026 will be entitled to vote.
1 · Reply
tankwfwf
tankwfwf Aug. 17 at 7:33 PM
$BLRX This scam is slowly sinking in the sun. Phil can't screw all of the people who invested in this lie. Remember he is a liar and a thief.
0 · Reply